Age-Related Macular Degeneration

In a video interview, Rishi P. Singh, MD, staff surgeon at Cleveland Clinic Cole Eye Institute, associate professor of ophthalmology at Lerner College of Medicine and Healio/OSN Board Member, discusses Highlights from ARVO 2021 in AMD, including 10-year data from The Age-Related Eye Disease Study 2 (AREDS2), APL-2 for geographic atrophy, clinical practice data on brolucizumab (Beovu, Novartis) and more.

In a video interview, Rishi P. Singh, MD, staff surgeon at Cleveland Clinic Cole Eye Institute, associate professor of ophthalmology at Lerner College of Medicine and Healio/OSN Board Member, discusses treating patients in real-world clinical practice, with a focus on vitamin therapy to prevent progression in dry AMD and a treat-and-extend approach for wet AMD.

In a video interview, Rishi P. Singh, MD, staff surgeon at Cleveland Clinic Cole Eye Institute, associate professor of ophthalmology at Lerner College of Medicine and Healio/OSN Board Member, discusses the greatest areas of unmet need, including needing other mechanisms of action to inhibit for treatment of wet AMD and addressing the progression of geographic atrophy in dry AMD.

Data from a 10-year follow-up study of the Age-Related Eye Disease Study 2 reaffirmed the safety and benefit of replacing beta-carotene with lutein-zeaxanthin in the original AREDS supplement, according to a presenter at the virtual Association for Research in Vision and Ophthalmology meeting.

Although improvement of services would be expected over the years, long-term outcomes of intravitreal injections have not changed over the past decade and are suboptimal, according to a big data analysis performed in the U.K.

Early detection of neovascular age-related macular degeneration improved when patients used an at-home monitoring system, according to a review published in the Journal of Clinical Medicine.

Timing of cataract surgery did not affect outcomes among patients with wet age-related macular degeneration, according to a study published in Acta Ophthalmologica.

Patients with neovascular age-related macular degeneration who had treatment delayed due to the COVID-19 pandemic experienced worsening of their disease activity, according to a study.

Jim Williamson, OD, FAAO, FORS, provided an overview of his SECO presentation that focused on evaluating the choroid and differentiating between diseases caused by age-related macular degeneration to those in the pachychoroid spectrum.

The pandemic’s impact on visual hallucinations in people with impaired vision and increased risks for age-related macular degeneration from air pollution led March retina/vitreous coverage on Healio/OSN.